Build with KISHO Sign In Sign Up

Kisho

Medicis Pharmaceutical Corp. — Rare Disease Pipeline | Kisho | Kisho

Medicis Pharmaceutical Corp.

Other

3

Orphan Designations

0

FDA Approvals

16

Rare Diseases

0

News Articles

Disease	Drug(s)	Designation	Approved
Susac syndrome	Ammonul	Orphan Designation	-
anti-glomerular basement membrane disease	Buphenyl	Orphan Designation	-
argininosuccinic aciduria	Buphenyl	Orphan Designation	-
citrullinemia type I	Buphenyl	Orphan Designation	-
citrullinemia, type II, adult-onset	Buphenyl	Orphan Designation	-
congenital lethal erythroderma	sodium phenylbutyrate	Orphan Designation	-
karyomegalic interstitial nephritis	Buphenyl	Orphan Designation	-
malignant carotid body paraganglioma	sodium phenylbutyrate	Orphan Designation	-
neurodegeneration with brain iron accumulation 5	Ammonul	Orphan Designation	-
post 5-alpha-reductase inhibitors treatment syndrome	sodium phenylbutyrate	Orphan Designation	-
post-treatment Lyme disease syndrome	sodium phenylbutyrate	Orphan Designation	-
sickle cell-beta-thalassemia disease syndrome	sodium phenylbutyrate	Orphan Designation	-
steroid-responsive encephalopathy associated with autoimmune thyroiditis	Ammonul	Orphan Designation	-
treatment-refractory schizophrenia	sodium phenylbutyrate	Orphan Designation	-
urea cycle disorder	Buphenyl	Orphan Designation	-
urea cycle disorder or inherited hyperammonemia	Buphenyl	Orphan Designation	-

← Back to Companies